First Trust Direct Indexing’s Takeda Pharmaceutical TAK Stock Holding History

First Trust Direct Indexing’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,755	Closed	-$580K	–	815
2024 Q3	$580K	Sell	40,755 -4,212	-9%	-$59.7K	0.03%	500
2024 Q2	$582K	Sell	44,967 -8,068	-15%	-$107K	0.04%	459
2024 Q1	$737K	Sell	53,035 -12,691	-19%	-$185K	0.05%	367
2023 Q4	$938K	Sell	65,726 -5,332	-8%	-$75.7K	0.08%	276
2023 Q3	$1.1M	Buy	71,058 +12,943	+22%	+$200K	0.13%	178
2023 Q2	$913K	Sell	58,115 -2,729	-4%	-$44.7K	0.1%	236
2023 Q1	$1M	Buy	60,844 +462	+0.8%	+$7.36K	0.12%	209
2022 Q4	$942K	Sell	60,382 -3,097	-5%	-$43.3K	0.12%	217
2022 Q3	$823K	Buy	63,479 +24,560	+63%	+$341K	0.12%	226
2022 Q2	$546K	Buy	38,919 +11,415	+42%	+$163K	0.08%	333
2022 Q1	$394K	Buy	+27,504	New	+$404K	0.05%	423
2021 Q4	–	Sell	-21,842	Closed	-$358K	–	687
2021 Q3	$358K	Buy	21,842 +768	+4%	+$12.9K	0.05%	426
2021 Q2	$355K	Buy	21,074 +10,696	+103%	+$182K	0.05%	422
2021 Q1	$190K	Buy	10,378 +1,306	+14%	+$23.5K	0.05%	379
2020 Q4	$165K	Buy	+9,072	New	+$159K	0.04%	387

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

First Trust Direct Indexing's TAK Position: Q4 2024 in Review

First Trust Direct Indexing sold out of Takeda Pharmaceutical (TAK) in Q4 2024, closing a stake of 40,755 shares — an estimated $580K sold.

First Trust Direct Indexing first reported a position in TAK in Q4 2020 and held it in 15 quarters. The position peaked at $1.1M in Q3 2023. 301 funds tracked by Wall St. Rank hold TAK as of Q4 2024.

First Trust Direct Indexing reported no remaining Takeda Pharmaceutical position as of Q4 2024 after selling out during the quarter.
First Trust Direct Indexing sold 40,755 Takeda Pharmaceutical shares in Q4 2024, an estimated $580K.
First Trust Direct Indexing first reported a position in Takeda Pharmaceutical in Q4 2020 and held it in 15 quarters.
First Trust Direct Indexing's Takeda Pharmaceutical position peaked at $1.1M in Q3 2023.
301 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2024.

Based on First Trust Direct Indexing's 13F filing for Q4 2024.